Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP1 | P07148 | 1/20 | 0.53 |
| ▸ | FABP6 | P51161 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8485638 | 0.81 | NPC1 (0.49) | MEN1ALDH1A1KMT2AEGFRKDM4E | |
| SCHEMBL28757289 | 0.78 | RECQL (0.44) | FABP1FABP6CXCR4KDM4EL3MBTL1 | |
| SCHEMBL15529224 | 0.77 | KDM5B (0.45) | FABP1FABP6BACE1MEN1ALDH1A1 | |
| SCHEMBL1413125 | 0.74 | FABP1 (0.67) | FABP1FABP6BACE1CXCR4MEN1 | |
| SCHEMBL1385358 | 0.73 | — | — | |
| SCHEMBL28475529 | 0.72 | FABP1 (0.64) | FABP1FABP6BACE1CXCR4MEN1 | |
| SCHEMBL8725876 | 0.72 | HSD17B10 (0.42) | MEN1ALDH1A1KMT2AKDM4ENPC1 | |
| SCHEMBL2021551 | 0.71 | EGLN2 (0.38) | MEN1KMT2AKDM4ENPC1 | |
| SCHEMBL2066722 | 0.70 | KDM4E (0.36) | MEN1ALDH1A1KMT2AEGFRKDM4E | |
| SCHEMBL2230559 | 0.69 | FABP1 (1.00) | FABP1FABP6BACE1CXCR4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903096-B2 | Quinazoline derivatives as medicaments | SCIOS, INC. (US) | 2005-06-07 | — | — | US | claimed |
| US-6476031-B1 | Quinazoline derivatives as medicaments | SCIOS, INC. | 2002-11-05 | — | — | US | claimed |
| US-5776954-A | GLUCAGON ANTAGONISTS | MERCK & CO., INC. (US) | 1998-07-07 | — | — | US | claimed |
| EP-2846803-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | Anvyl, LLC (US) | 2015-03-18 | — | — | EP | disclosed |
| CN-104334175-A | Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof | ANVYL LLC | 2015-02-04 | — | — | CN | disclosed |
| WO-2013169889-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | ANVYL LLC (US) | 2013-11-14 | — | — | WO | disclosed |
| US-7345045-B2 | Pyrido-pyrimidine compounds as medicaments | SCIOS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1107959-B1 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS INC (US) | 2006-10-11 | — | — | EP | disclosed |
| US-20050220784-A1 | Quinazoline derivatives as medicaments | SCIOS, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| US-20050171123-A1 | Quinazoline derivatives as medicaments | SCIOS, INC. | 2005-08-04 | — | — | US | disclosed |
| US-6903096-B2 | Quinazoline derivatives as medicaments | SCIOS, INC. (US) | 2005-06-07 | — | — | US | disclosed |
| US-6476031-B1 | Quinazoline derivatives as medicaments | SCIOS, INC. | 2002-11-05 | — | — | US | disclosed |
| US-6277989-B1 | USEFUL IN TREATING CONDITIONS THAT ARE CHARACTERIZED BY ENHANCED P38 KINASE ACTIVITY AND/OR TRANSFORMING GROWTH FACTOR BETA (TGF-.BETA.) ACTIVITY SUCH AS INFLAMMATION, PROLIFERATIVE DISEASES, AND CERTAIN CARDIOVASCULAR DISORDERS | SCIOS, INC. | 2001-08-21 | — | — | US | disclosed |
| EP-0859771-A4 | SUBSTITUTED PYRIDYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO INC (US) | 2000-03-15 | — | — | EP | disclosed |
| EP-0859771-A1 | SUBSTITUTED PYRIDYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck & Co., Inc. (US) | 1998-08-26 | — | — | EP | disclosed |
| US-5776954-A | GLUCAGON ANTAGONISTS | MERCK & CO., INC. (US) | 1998-07-07 | — | — | US | disclosed |
| WO-1997016442-A1 | SUBSTITUTED PYRIDYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171123-A1 | Quinazoline derivatives as medicaments | TGFBR2, SMAD2, ADRB2 | FABP1 4464/4885FABP6 4137/4885BACE1 1431/4885 |
| US-20050220784-A1 | Quinazoline derivatives as medicaments | TGFBR2, SMAD2, ADRB2 | FABP1 4464/4885FABP6 4137/4885BACE1 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.